Cargando…

Impact of chemotherapy alone, and chemotherapy plus ipilimumab, on circulating immune cells in patients with metastatic bladder cancer

Detalles Bibliográficos
Autores principales:	Galsky, Matthew D, Noah, Hahn, Starodub, Alexander, Hauke, Ralph J, Twardowski, Przemyslaw, Fleming, Mark, Qi, Jingjing, Sonpavde, Guru, Patel, Manishkumar, Zhu, Jun, Chippada-Venkata, Uma, Albany, Costantine, Wang, Li, Merad, Miriam, Oh, William, Bhardwaj, Nina, Gnjatic, Sacha, Kim-Schulze, Seunghee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649313/ http://dx.doi.org/10.1186/2051-1426-3-S2-P257

Ejemplares similares

Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy
por: Ranganath, Praveen, et al.
Publicado: (2015)

Epigenetics in Prostate Cancer
por: Albany, Costantine, et al.
Publicado: (2011)

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Lohiya, Vipin, et al.
Publicado: (2016)

Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer
por: Anker, Jonathan, et al.
Publicado: (2023)

Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States
por: Galsky, Matthew D., et al.
Publicado: (2018)

Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
por: Jun, Tomi, et al.
Publicado: (2022)

Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer
por: Albany, Costantine, et al.
Publicado: (2014)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Anti-myelin-associated glycoprotein peripheral neuropathy as the only presentation of low grade lymphoma: a case report
por: Albany, Costantine
Publicado: (2009)

Systemic immune-inflammation index in germ-cell tumours: search for a biological prognostic biomarker
por: Albany, Costantine
Publicado: (2018)

Disabling osteomalacia and myopathy as the only presenting features of celiac disease: a case report
por: Albany, Costantine, et al.
Publicado: (2009)

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
por: Dummer, Reinhard, et al.
Publicado: (2015)

First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
por: Cao, Xueqiong, et al.
Publicado: (2022)

Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer
por: Derks, Sarah, et al.
Publicado: (2022)

Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy
por: Nishimura, Tomoka, et al.
Publicado: (2022)

Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Prostate Cancer Progression
por: Gong, Yixuan, et al.
Publicado: (2014)

Germ Cell Tumors: Updates on Epidemiology, Biology, and Treatment Considerations
por: Bagrodia, Aditya, et al.
Publicado: (2018)

Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma(1)
por: Leiter, Amanda, et al.
Publicado: (2016)

510. Elevated IL-1β level as a predictor of inflammation and death in COVID-19
por: Swartz, Talia H, et al.
Publicado: (2020)

Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2015)

Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Hongman, et al.
Publicado: (2018)

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Yang, Szu-Chun, et al.
Publicado: (2021)

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
por: Maki, Robert G., et al.
Publicado: (2013)

Epstein-Barr virus myelitis and Castleman's disease in a patient with acquired immune deficiency syndrome: a case report
por: Albany, Costantine, et al.
Publicado: (2011)

An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer
por: Jiang, Panpan, et al.
Publicado: (2021)

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
por: Dummer, Reinhard, et al.
Publicado: (2014)

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma
por: Namikawa, Kenjiro, et al.
Publicado: (2020)

Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585]
por: Bhardwaj, Nina, et al.
Publicado: (2014)

Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs
por: Alabanza, Leah, et al.
Publicado: (2014)

A robust blood gene expression-based prognostic model for castration-resistant prostate cancer
por: Wang, Li, et al.
Publicado: (2015)

Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma
por: Yang, Liu, et al.
Publicado: (2022)

A remarkable response to combination chemotherapy with nivolumab and ipilimumab in a patient with primary pulmonary choriocarcinoma: a case report
por: Iso, Hirokazu, et al.
Publicado: (2023)

Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report
por: Kunimatsu, Yusuke, et al.
Publicado: (2023)

Ipilimumab
Publicado: (2012)

Circulating Biomarkers in Bladder Cancer
por: Nandagopal, Lakshminarayanan, et al.
Publicado: (2016)

Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer
por: Gourdin, Theodore, et al.
Publicado: (2018)

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer
por: Thomas, Jonathan, et al.
Publicado: (2022)

Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression
por: Gong, Yixuan, et al.
Publicado: (2016)

Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C)
por: Gruber, Conor, et al.
Publicado: (2020)

Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
por: Aleman, Adolfo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rg1fiv2gok3u9gf0u3rpekur4l